

Sarah Blach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6822920/publications.pdf>

Version: 2024-02-01

60
papers

7,097
citations

270111

25
h-index

206121

51
g-index

60
all docs

60
docs citations

60
times ranked

8329
citing authors

#	ARTICLE	IF	CITATIONS
1	HCV disease burden and population segments in Switzerland. <i>Liver International</i> , 2022, 42, 330-339.	1.9	14
2	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	3.7	237
3	Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting. <i>Liver International</i> , 2022, 42, 1930-1934.	1.9	10
4	Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach. <i>BMC Infectious Diseases</i> , 2022, 22, 397.	1.3	3
5	Impact of COVID-19 on global HCV elimination efforts. <i>Journal of Hepatology</i> , 2021, 74, 31-36.	1.8	189
6	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	1.0	28
7	Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 169-184.	3.7	24
8	Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19. <i>Liver International</i> , 2021, 41, 2024-2031.	1.9	9
9	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. <i>Liver International</i> , 2020, 40, 1545-1555.	1.9	37
10	Global prevalence of hepatitis C virus in children in 2018: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 374-392.	3.7	80
11	Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2020, 56, 325-329.	0.2	5
12	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. <i>Addiction</i> , 2019, 114, 150-166.	1.7	178
13	Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 794-804.	3.7	68
14	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. <i>Clinical Infectious Diseases</i> , 2019, 69, 2218-2227.	2.9	52
15	THU-403-The consensus hepatitis C cascade of care: Methodology and initial findings from three countries. <i>Journal of Hepatology</i> , 2019, 70, e333-e334.	1.8	1
16	THU-397-Screening strategies for hepatitis C virus elimination in Italy. <i>Journal of Hepatology</i> , 2019, 70, e330.	1.8	0
17	Screening strategies for Hepatitis C Virus elimination in Italy. <i>Digestive and Liver Disease</i> , 2019, 51, e68.	0.4	0
18	HCV Burden and Barriers to Elimination in the Middle East. <i>Clinical Liver Disease</i> , 2019, 14, 224-227.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. <i>Swiss Medical Weekly</i> , 2019, 149, w20026.	0.8	9
20	Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. <i>Swiss Medical Weekly</i> , 2019, 149, w14694.	0.8	7
21	Forecasting liver disease burden. <i>Digestive and Liver Disease</i> , 2018, 50, 10-11.	0.4	0
22	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	3.7	1,241
23	The global prevalence of HBsAg by age in 2016 and the case for universal treatment in low and middle income countries. <i>Journal of Hepatology</i> , 2018, 68, S169.	1.8	1
24	Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. <i>PLoS ONE</i> , 2018, 13, e0209374.	1.1	12
25	Quantifying the impact of achieving the World Health Organization global health sector strategy goals for hepatitis C in the EURO region. <i>Journal of Hepatology</i> , 2018, 68, S147-S148.	1.8	0
26	Quantifying the impact of achieving the World Health Organization global health sector strategy goals for hepatitis C in the African Region. <i>Journal of Hepatology</i> , 2018, 68, S148-S149.	1.8	0
27	The current and future disease burden of hepatitis B in the general population and among five year olds in the Eastern Mediterranean Region. <i>Journal of Hepatology</i> , 2018, 68, S165.	1.8	0
28	Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the "underwater portion of the iceberg" matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?. <i>Journal of Hepatology</i> , 2018, 68, S149-S150.	1.8	0
29	Elimination of hepatitis C in two different Swiss regions " A model-based microelimination scenario. <i>Journal of Hepatology</i> , 2018, 68, S176.	1.8	0
30	Disease burden of hepatitis C in the Austrian state of Tyrol " Epidemiological data and model analysis to achieve elimination by 2030. <i>PLoS ONE</i> , 2018, 13, e0200750.	1.1	6
31	Hepatitis C infection in the Pan American Health Organization Region: The current burden of disease and a road map for achieving the WHO Global Health Sector Strategy Goals. <i>Journal of Hepatology</i> , 2018, 68, S164-S165.	1.8	1
32	HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. <i>PLoS ONE</i> , 2018, 13, e0202109.	1.1	24
33	Forecasting Hepatitis C liver disease burden on real-life data. Does the "hidden iceberg" matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	1.9	33
34	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
35	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	3.7	208
36	HCV elimination among people who inject drugs. What would happen after the WHO HCV elimination target is achieved?. <i>Journal of Hepatology</i> , 2017, 66, S405-S406.	1.8	1

#	ARTICLE	IF	CITATIONS
37	Strategies to manage hepatitis C virus infection disease burdenâ€”Volume 4. Journal of Viral Hepatitis, 2017, 24, 44-63.	1.0	17
38	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. Journal of Viral Hepatitis, 2017, 24, 25-43.	1.0	26
39	Historical epidemiology of hepatitis C virus in select countriesâ€”volume 4. Journal of Viral Hepatitis, 2017, 24, 8-24.	1.0	30
40	Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Medical Weekly, 2017, 147, w14543.	0.8	12
41	Achieving WHO recommendations for Hepatitis C Virus Elimination in Belgium. Acta Gastro-Enterologica Belgica, 2016, 79, 222-6.	0.4	6
42	Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastro-Enterologica Belgica, 2016, 79, 227-32.	0.4	5
43	Strategies to manage hepatitis C virus infection disease burden â€” volume 3. Journal of Viral Hepatitis, 2015, 22, 42-65.	1.0	62
44	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm â€” volume 3. Journal of Viral Hepatitis, 2015, 22, 21-41.	1.0	61
45	Historical epidemiology of hepatitis C virus (<sc>HCV</sc>) in select countries â€” volume 3. Journal of Viral Hepatitis, 2015, 22, 4-20.	1.0	109
46	Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE, 2015, 10, e0125214.	1.1	25
47	Interferon-Based Hepatitis C Antiviral Treatment Outcomes May Be Predicted by Alanine Aminotransferase Levels. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 407-408.	0.8	1
48	The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scandinavian Journal of Gastroenterology, 2015, 50, 233-244.	0.6	33
49	Historical epidemiology of hepatitis C virus (<sc>HCV</sc>) in select countries â€” volume 2. Journal of Viral Hepatitis, 2015, 22, 6-25.	1.0	92
50	Strategies to manage hepatitis <sc>C</sc> virus (<sc>HCV</sc>) infection disease burden â€” volume 2. Journal of Viral Hepatitis, 2015, 22, 46-73.	1.0	47
51	The present and future disease burden of hepatitis <sc>C</sc> virus (<sc>HCV</sc>) infections with today's treatment paradigm â€” volume 2. Journal of Viral Hepatitis, 2015, 22, 26-45.	1.0	117
52	P0714 : Impact of prioritizing treatment in a high resource setting - minimizing the burden of HCV related disease in 15 years. Journal of Hepatology, 2015, 62, S591-S592.	1.8	5
53	P1243 : Birth cohort distribution and screening of viremic HCV infections in luxembourg. Journal of Hepatology, 2015, 62, S823.	1.8	0
54	Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Medical Weekly, 2015, 145, w14221.	0.8	8

#	ARTICLE	IF	CITATIONS
55	The Disease Burden of Hepatitis C in Belgium: An update of a realistic disease control strategy. <i>Acta Gastro-Enterologica Belgica</i> , 2015, 78, 228-32.	0.4	1
56	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89.	1.0	161
57	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014, 21, 34-59.	1.0	372
58	Historical epidemiology of hepatitis C virus (HCV) in selected countries. <i>Journal of Viral Hepatitis</i> , 2014, 21, 5-33.	1.0	211
59	Global epidemiology and genotype distribution of the hepatitis C virus infection. <i>Journal of Hepatology</i> , 2014, 61, S45-S57.	1.8	1,560
60	Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. <i>BMC Gastroenterology</i> , 2014, 14, 137.	0.8	34